NYSE:ZYME - Zymeworks Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $13.19 -0.76 (-5.45 %) (As of 07/20/2018 04:00 PM ET)Previous Close$13.19Today's Range$13.15 - $14.1652-Week Range$6.25 - $29.00Volume133,512 shsAverage Volume95,746 shsMarket Capitalization$445.71 millionP/E Ratio-23.14Dividend YieldN/ABeta5.77 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Receive ZYME News and Ratings via Email Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:ZYME CUSIPN/A Webwww.zymeworks.com Phone604-678-1388 Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09 Price-To-Earnings Trailing P/E Ratio-23.14 Forward P/E Ratio-5.36 P/E GrowthN/A Sales & Book Value Annual Sales$51.76 million Price / Sales8.14 Cash FlowN/A Price / CashN/A Book Value$4.59 per share Price / Book2.87 Profitability EPS (Most Recent Fiscal Year)($0.57) Net Income$-10,400,000.00 Net Margins-30.41% Return on Equity-16.07% Return on Assets-13.65% Miscellaneous Employees147 Outstanding Shares31,950,000Market Cap$445.71 Zymeworks (NYSE:ZYME) Frequently Asked Questions What is Zymeworks' stock symbol? Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME." How were Zymeworks' earnings last quarter? Zymeworks Inc (NYSE:ZYME) issued its quarterly earnings data on Tuesday, May, 1st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.15. The firm earned $0.04 million during the quarter. Zymeworks had a negative return on equity of 16.07% and a negative net margin of 30.41%. View Zymeworks' Earnings History. When is Zymeworks' next earnings date? Zymeworks is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Zymeworks. What price target have analysts set for ZYME? 7 analysts have issued 1-year target prices for Zymeworks' stock. Their predictions range from $15.00 to $37.00. On average, they anticipate Zymeworks' stock price to reach $24.00 in the next year. This suggests a possible upside of 82.0% from the stock's current price. View Analyst Ratings for Zymeworks. What is the consensus analysts' recommendation for Zymeworks? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Zymeworks' key competitors? Some companies that are related to Zymeworks include AnaptysBio (ANAB), PTC Therapeutics (PTCT), Aimmune Therapeutics (AIMT), G1 Therapeutics (GTHX), Corcept Therapeutics (CORT), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), IMMURON Ltd/S (IMRN), Mirati Therapeutics (MRTX), Innoviva (INVA), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN) and Deciphera Pharmaceuticals (DCPH). Who are Zymeworks' key executives? Zymeworks' management team includes the folowing people: Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 46)Mr. Neil Klompas C.A., C.P.A., CPA, CA, Chief Financial Officer (Age 46)Dr. Diana F. Hausman, Chief Medical Officer (Age 55)Dr. Donald L. Drakeman Ph.D., J.D., Special Advisor (Age 64)Mr. David Tucker, Chief Operating Officer When did Zymeworks IPO? (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Has Zymeworks been receiving favorable news coverage? Media headlines about ZYME stock have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zymeworks earned a media sentiment score of 0.07 on Accern's scale. They also gave news headlines about the company an impact score of 46.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. How do I buy shares of Zymeworks? Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zymeworks' stock price today? One share of ZYME stock can currently be purchased for approximately $13.19. How big of a company is Zymeworks? Zymeworks has a market capitalization of $445.71 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe. How can I contact Zymeworks? Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected] MarketBeat Community Rating for Zymeworks (NYSE ZYME)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 98 (Vote Outperform)Underperform Votes: 79 (Vote Underperform)Total Votes: 177MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?